SeaStar Medical Holding Corporation (ICU), a commercial-stage medical device company, is slated to host a conference call on Wednesday at 4.30 p.m. ET, to provide business updates and pipeline progress.
The company focuses on advancing cell-directed extracorporeal therapy for treating hyperinflammation, which includes approved Quelimmune, a selective cytopheretic device (SCD).
The SCD has received breakthrough designations from the FDA for 4 indications namely Adult Acute kidney Injury, Cardiorenal Syndrome, Hepatorenal Syndrome, and Chronic systemic Inflammation in End-stage renal disease.
NEUTRALIZE-AKI trial is currently evaluating the safety and efficacy of SCD in Adult Acute Kidney injury patients requiring CRRT (Continuous Renal Replacement Therapy).
ICU is currently trading at $2.17, up 0.46%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.